MARKET

AFMD

AFMD

Affimed
NASDAQ
0.7811
-0.0239
-2.97%
After Hours: 0.8045 +0.0234 +3.00% 18:31 03/28 EDT
OPEN
0.8100
PREV CLOSE
0.8050
HIGH
0.8396
LOW
0.7700
VOLUME
75.30K
TURNOVER
--
52 WEEK HIGH
8.95
52 WEEK LOW
0.7700
MARKET CAP
12.80M
P/E (TTM)
-0.1535
1D
5D
1M
3M
1Y
5Y
1D
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Barchart · 5d ago
Weekly Report: what happened at AFMD last week (0317-0321)?
Weekly Report · 6d ago
Weekly Report: what happened at AFMD last week (0310-0314)?
Weekly Report · 03/17 12:17
Weekly Report: what happened at AFMD last week (0303-0307)?
Weekly Report · 03/10 12:19
Weekly Report: what happened at AFMD last week (0224-0228)?
Weekly Report · 03/03 12:18
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Barchart · 03/03 05:30
Weekly Report: what happened at AFMD last week (0217-0221)?
Weekly Report · 02/24 12:18
Weekly Report: what happened at AFMD last week (0210-0214)?
Weekly Report · 02/17 12:14
More
About AFMD
More
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Recently
Symbol
Price
%Change

Webull offers Affimed NV stock information, including NASDAQ: AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.